61. A Phase 3 Trial of Brepocitinib in Dermatomyositis.
作者: Ruth Ann Vleugels.;Julie J Paik.;Iazsmin Bauer Ventura.;Aaron R Mangold.;Prateek C Gandiga.;Anna Haemel.;Hector Chinoy.;Yessar M Hussain.;Kumaraswamy Sivakumar.;Griger Zoltan.;Eun Bong Lee.;Francisca Bozan.;Chung-Yuan Hsu.;Alisa Femia.;Mazen M Dimachkie.;Michelle S Min.;Tahseen Mozaffar.;Christina Charles-Schoeman.;David R Fernandez.;Oluwakemi Onajin.;Raquel Marques.;Galina Marder.;Floranne Ernste.;Elena Schiopu.;Jason Sluzevich.;David Pearson.;Stephen Lindsey.;Michael Luggen.;Michael R Bubb.;Erin Boh.;Rashmi Maganti.;Latisha Heinlen.;Katharina S Shaw.;Matthew D Cascino.;Paul N Mudd.;Jiri Vencovsky.;Anthony P Fernandez.;David Fiorentino.;Lisa Christopher-Stine.;Victoria P Werth.;Rohit Aggarwal.; .
来源: N Engl J Med. 2026年
Brepocitinib is a first-in-class, oral, selective TYK2-JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis.
65. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
作者: Yong-Joon Lee.;Seung-Jun Lee.;Jin Won Kim.;Sang-Hyup Lee.;Gwang-Sil Kim.;Jae Hyoung Park.;Jin-Man Cho.;Woong Chol Kang.;Hyuck-Jun Yoon.;Won Ho Kim.;Seung-Jin Lee.;Jin Bae Lee.;Ji-Yong Jang.;Sanghoon Shin.;Ik Hyun Park.;Sung Uk Kwon.;Sunwon Kim.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Byeong-Keuk Kim.; .
来源: N Engl J Med. 2026年394卷14期1365-1375页
Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease remains limited.
|